Verastem Inc Total Liabilities
Verastem Inc total liabilities. Based on the latest financial reports, Verastem Inc (VSTM) has total liabilities worth $156.53 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check VSTM asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Verastem Inc (2010–2025)
Total liabilities of Verastem Inc from 2010 to 2025. This chart illustrates how Verastem Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Verastem Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Verastem Inc Competitors by Total Liabilities
The table below lists competitors of Verastem Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MAS Real Estate Inc
JSE:MSP
|
South Africa | ZAC497.74 Million |
|
Shanghai Join Buy Co Ltd
SHG:600838
|
China | CN¥125.27 Million |
|
Shanghai Kaibao Pharmaceutical
SHE:300039
|
China | CN¥308.94 Million |
|
AhnLab Inc
KQ:053800
|
Korea | ₩139.78 Billion |
|
Ningbo Dechang Electrical Machinery Made Co Ltd
SHG:605555
|
China | CN¥2.19 Billion |
|
Lions Gate Entertainment Corp
NYSE:LGF-A
|
USA | $7.32 Billion |
|
Viglacera Corp JSC
VN:VGC
|
Vietnam | ₫15.93 Trillion |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
China | CN¥1.84 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Verastem Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Verastem Inc's balance sheet.
Liquidity & Leverage Metrics
Verastem Inc Total Liabilities Ratios Explained
Verastem Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verastem Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verastem Inc (2010–2025)
The table below shows the annual total liabilities of Verastem Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $189.25 Million | +45.09% |
| 2024-12-31 | $130.43 Million | +41.24% |
| 2023-12-31 | $92.34 Million | +93.76% |
| 2022-12-31 | $47.66 Million | +125.84% |
| 2021-12-31 | $21.10 Million | -45.99% |
| 2020-12-31 | $39.08 Million | -71.66% |
| 2019-12-31 | $137.87 Million | -9.85% |
| 2018-12-31 | $152.94 Million | +376.34% |
| 2017-12-31 | $32.11 Million | +183.33% |
| 2016-12-31 | $11.33 Million | +6.65% |
| 2015-12-31 | $10.62 Million | +7.51% |
| 2014-12-31 | $9.88 Million | +26.46% |
| 2013-12-31 | $7.82 Million | +218.07% |
| 2012-12-31 | $2.46 Million | -96.58% |
| 2011-12-31 | $71.80 Million | +19411.68% |
| 2010-12-31 | $368.00K | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more